ATE446968T1 - Dominant-negative varianten der methionin- aminopeptidase 2 (metap2) und klinische verwendungen davon - Google Patents

Dominant-negative varianten der methionin- aminopeptidase 2 (metap2) und klinische verwendungen davon

Info

Publication number
ATE446968T1
ATE446968T1 AT02761229T AT02761229T ATE446968T1 AT E446968 T1 ATE446968 T1 AT E446968T1 AT 02761229 T AT02761229 T AT 02761229T AT 02761229 T AT02761229 T AT 02761229T AT E446968 T1 ATE446968 T1 AT E446968T1
Authority
AT
Austria
Prior art keywords
metap2
methionine
dominant
aminoopeptidase
negative variants
Prior art date
Application number
AT02761229T
Other languages
English (en)
Inventor
Yie-Hwa Chang
Original Assignee
Univ Saint Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saint Louis filed Critical Univ Saint Louis
Application granted granted Critical
Publication of ATE446968T1 publication Critical patent/ATE446968T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02761229T 2001-08-30 2002-08-02 Dominant-negative varianten der methionin- aminopeptidase 2 (metap2) und klinische verwendungen davon ATE446968T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/943,123 US20020182701A1 (en) 2001-08-30 2001-08-30 Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof
PCT/US2002/024661 WO2003020881A2 (en) 2001-08-30 2002-08-02 DOMINANT NEGATIVE VARIANTS OF METHIONINE AMINOPEPTIDASE 2 (MetAP2) AND CLINICAL USES THEREOF

Publications (1)

Publication Number Publication Date
ATE446968T1 true ATE446968T1 (de) 2009-11-15

Family

ID=25479147

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02761229T ATE446968T1 (de) 2001-08-30 2002-08-02 Dominant-negative varianten der methionin- aminopeptidase 2 (metap2) und klinische verwendungen davon

Country Status (6)

Country Link
US (2) US20020182701A1 (de)
EP (1) EP1572884B1 (de)
AT (1) ATE446968T1 (de)
AU (1) AU2002326509A1 (de)
DE (1) DE60234215D1 (de)
WO (1) WO2003020881A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878552A1 (de) 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molekularer Nachweis von chromosomalen Veränderungen
JP2002513587A (ja) 1998-05-04 2002-05-14 ダコ エー エス 染色体異常を検出するための方法およびプローブ
WO2006010498A2 (en) * 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)
WO2008076922A1 (en) * 2006-12-15 2008-06-26 Ceres, Inc. Modulation of plant protein levels
US20130191941A1 (en) 2006-07-05 2013-07-25 Shing Kwok Modulating light response pathways in plants, increasing light-related tolerances in plants, and increasing biomass in plants
EP2255003B1 (de) 2008-02-15 2015-01-28 Ceres Inc. Dürre- und hitzetoleranz bei pflanzen
US9151743B2 (en) * 2008-11-06 2015-10-06 Merck Patent Gmbh Use of EEF1A as biomarker and a method of screening MetAP2 inhibitors
US20120297505A1 (en) 2009-07-20 2012-11-22 Chuan-Yin Wu Transgenic plants having increased biomass
WO2011140329A1 (en) 2010-05-06 2011-11-10 Ceres, Inc. Transgenic plants having increased biomass
WO2012058223A1 (en) 2010-10-27 2012-05-03 Ceres, Inc. Transgenic plants having altered biomass composition
WO2013067128A1 (en) 2011-11-02 2013-05-10 Ceres, Inc. Transgenic plants having increased tolerance to aluminum
WO2013086499A2 (en) 2011-12-09 2013-06-13 Ceres, Inc. Transgenic plants having altered biomass composition
US9101100B1 (en) 2014-04-30 2015-08-11 Ceres, Inc. Methods and materials for high throughput testing of transgene combinations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5255593A (en) * 1975-10-30 1977-05-07 Ajinomoto Kk Measuring method of enzyme activity
NL7607684A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
NL9401886A (nl) * 1994-05-27 1996-01-02 Dsm Nv Samenstelling bestaande uit een dendrimeer en een in het dendrimeer opgesloten actieve stof, een werkwijze voor de bereiding van een dergelijke samenstelling en een werkwijze voor het vrijgeven van de actieve stof.
CA2194014C (en) * 1994-06-17 2009-10-06 Trobe University (La) Biological control of insects
US5888796A (en) * 1996-01-31 1999-03-30 St. Louis University Clone of a nucleotide sequence encoding a protein having two functions
US6110744A (en) * 1996-11-13 2000-08-29 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
AU755387B2 (en) * 1997-12-16 2002-12-12 Japan Tobacco Inc. Polypeptides having aminopeptidase activity and nucleic acids encoding same
US6261794B1 (en) * 1999-10-14 2001-07-17 Saint Louis University Methods for identifying inhibitors of methionine aminopeptidases
US6136604A (en) * 1999-10-27 2000-10-24 Isis Pharmaceuticals Inc. Antisense inhibition of methionine aminopeptidase 2 expression

Also Published As

Publication number Publication date
US20050032221A1 (en) 2005-02-10
AU2002326509A8 (en) 2005-11-17
US20020182701A1 (en) 2002-12-05
AU2002326509A1 (en) 2003-03-18
EP1572884A4 (de) 2007-03-21
DE60234215D1 (de) 2009-12-10
EP1572884B1 (de) 2009-10-28
WO2003020881A3 (en) 2005-09-15
WO2003020881A2 (en) 2003-03-13
EP1572884A2 (de) 2005-09-14

Similar Documents

Publication Publication Date Title
DE60234215D1 (de) Dominant-negative varianten der methionin-aminopeptidase 2 (metap2) und klinische verwendungen davon
EP1363920A4 (de) Modifizierte psma-liganden und deren verwendung
EP1576130A4 (de) Nukleinsäuren und entsprechende proteine mit der bezeichnung 282p1g3 mit eignung zur behandlung und zum nachweis von krebs
EA200500143A1 (ru) Азолидинонвинильные производные конденсированного бензола
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
BRPI0413449A (pt) compostos de quinoxalina
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
DK1636561T3 (da) Kombinatorisk proteinbiblioteksscreening ved hjælp af periplasmatisk ekspression
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
ATE398630T1 (de) Zyklische conotoxin-peptide
DE60230722D1 (de) Il-8-rezeptor-antagonisten
DE60331598D1 (de) Verabreichung von anti-tnf-alpha f(ab')2 antikörper-fragmenten
ATE312096T1 (de) Neue verbindungen
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
EA200301187A1 (ru) Применение азитромицина для производства лекарственного средства для лечения неинфекционных воспалительных заболеваний
FR2840307B1 (fr) Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
WO2004099240A3 (en) Peptides and mixtures thereof for use in the detection of severe acute respiratory syndrome-associated coronavirus (sars)
SE0302304D0 (sv) Novel compounds
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos
EA200600639A1 (ru) Пептид, происходящий из вируса гепатита с
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose
EA200600657A1 (ru) Новая комбинация антиатеротромботического средства и средства, предотвращающего агрегацию тромбоцитов
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties